169 related articles for article (PubMed ID: 31294925)
1. Impact of pharmacy services on cystic fibrosis transmembrane conductance regulator modulator prescribing at a pediatric cystic fibrosis center.
Wright BA; Singh SB; Schultz JL; Ramsey LJ; Spading KA; Mascardo LA; Starner TD
Pediatr Pulmonol; 2019 Oct; 54(10):1591-1595. PubMed ID: 31294925
[TBL] [Abstract][Full Text] [Related]
2. Unlocking the power of pharmacy services and accelerating access to medications: An update to the impact of pharmacy services on cystic fibrosis transmembrane conductance regulator modulator prescribing at a pediatric cystic fibrosis center.
Wright BA; Knockel LM
Pediatr Pulmonol; 2024 Feb; 59(2):526-527. PubMed ID: 38018663
[No Abstract] [Full Text] [Related]
3. Impact of pharmacy technicians as part of an integrated health-system pharmacy team on improvement of medication access in the care of cystic fibrosis patients.
Zobell JT; Moss J; Heuser SM; Asfour F
Pediatr Pulmonol; 2020 Dec; 55(12):3351-3357. PubMed ID: 32876997
[TBL] [Abstract][Full Text] [Related]
4. Analysis of prior authorization success and timeliness at a community-based specialty care pharmacy.
Hecht B; Frye C; Holland W; Holland CR; Rhodes LA; Marciniak MW
J Am Pharm Assoc (2003); 2021; 61(4S):S173-S177. PubMed ID: 33618986
[TBL] [Abstract][Full Text] [Related]
5. Increasing Access to Hepatitis C Virus Medications: A Program Model Using Patient Navigators and Specialty Pharmacy to Obtain Prior Authorization Approval.
Vu TM; Toribio W; Riazi F; Ciprian G; Gibbs N; Giardina M; Camacho JA; Parrella K; Cambe J; Amory C; Chasan R; Sigel KM; Weiss JJ
J Manag Care Spec Pharm; 2018 Apr; 24(4):329-333. PubMed ID: 29578854
[TBL] [Abstract][Full Text] [Related]
6. Impact of a cystic fibrosis transmembrane conductance regulator (CFTR) modulator on high-dose ibuprofen therapy in pediatric cystic fibrosis patients.
Bruch BA; Singh SB; Ramsey LJ; Starner TD
Pediatr Pulmonol; 2018 Aug; 53(8):1035-1039. PubMed ID: 29717552
[TBL] [Abstract][Full Text] [Related]
7. Assessment of long-term medication adherence with cystic fibrosis: An integrated approach.
Platt T; Kormelink LN; Autry EB; Rossoll SJ; Kuhn RJ
Pediatr Pulmonol; 2024 Feb; 59(2):458-464. PubMed ID: 38018665
[TBL] [Abstract][Full Text] [Related]
8. Understanding the expanding role of pharmacy services in outpatient cystic fibrosis care.
Zobell JT; Moss J; Heuser S; Roe L; Young DC
Pediatr Pulmonol; 2021 Jun; 56(6):1378-1385. PubMed ID: 33470556
[TBL] [Abstract][Full Text] [Related]
9. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
10. Comparison of time to treatment initiation of specialty medications between an integrated health system specialty pharmacy and external specialty pharmacies.
Russell M; McCoy H; Platt T; Zeltner M; Rhudy C
J Manag Care Spec Pharm; 2024 Apr; 30(4):352-362. PubMed ID: 38555622
[TBL] [Abstract][Full Text] [Related]
11. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.
Ren CL; Morgan RL; Oermann C; Resnick HE; Brady C; Campbell A; DeNagel R; Guill M; Hoag J; Lipton A; Newton T; Peters S; Willey-Courand DB; Naureckas ET
Ann Am Thorac Soc; 2018 Mar; 15(3):271-280. PubMed ID: 29342367
[TBL] [Abstract][Full Text] [Related]
12. Impact of a pharmacy technician and pharmacist on time to inhaled tobramycin therapy in a pediatric cystic fibrosis clinic.
Burrus TE; Vogt H; Pettit RS
Pediatr Pulmonol; 2021 Sep; 56(9):2861-2867. PubMed ID: 34191410
[TBL] [Abstract][Full Text] [Related]
13. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
Burgener EB; Moss RB
Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
[TBL] [Abstract][Full Text] [Related]
14. Changing landscape: psychological care in the era of cystic fibrosis transmembrane conductance regulator modulators.
Havermans T; Duff AJA
Curr Opin Pulm Med; 2020 Nov; 26(6):696-701. PubMed ID: 32941351
[TBL] [Abstract][Full Text] [Related]
15. Cystic fibrosis transmembrane conductance regulator (CFTR)-mediated residual chloride secretion does not protect against early chronic Pseudomonas aeruginosa infection in F508del homozygous cystic fibrosis patients.
Derichs N; Mekus F; Bronsveld I; Bijman J; Veeze HJ; von der Hardt H; Tummler B; Ballmann M
Pediatr Res; 2004 Jan; 55(1):69-75. PubMed ID: 14605249
[TBL] [Abstract][Full Text] [Related]
16. The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy.
Lommatzsch ST; Taylor-Cousar JL
Ther Adv Respir Dis; 2019; 13():1753466619844424. PubMed ID: 31027466
[TBL] [Abstract][Full Text] [Related]
17. Analyzing the costs of developing and operating an integrated health-system specialty pharmacy: The case of a centralized insurance navigation process for specialty clinic patients.
Rim MH; Thomas KC; Barrus SA; Ryther AMK; Clawson A; Ferrara F; Jackson CG
Am J Health Syst Pharm; 2021 May; 78(11):982-988. PubMed ID: 33693452
[TBL] [Abstract][Full Text] [Related]
18. Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function.
Zhang S; Shrestha CL; Kopp BT
Sci Rep; 2018 Nov; 8(1):17066. PubMed ID: 30459435
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of cystic fibrosis treatment.
Carter SC; McKone EF
Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265
[TBL] [Abstract][Full Text] [Related]
20. Impact of pharmacy services on cystic fibrosis medication adherence.
Zobell JT; Schwab E; Collingridge DS; Ball C; Nohavec R; Asfour F
Pediatr Pulmonol; 2017 Aug; 52(8):1006-1012. PubMed ID: 28608652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
